Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 349

    1.

    Luminal B breast tumors are not HER2 positive.

    Bhargava R, Dabbs DJ.

    Breast Cancer Res. 2008;10(5):404; author reply 405. Epub 2008 Sep 26. No abstract available.

    PMID:
    18831725
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    HER2 as a prognostic factor in breast cancer.

    Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.

    Oncology. 2001;61 Suppl 2:67-72. Review.

    PMID:
    11694790
    [PubMed - indexed for MEDLINE]
    3.

    Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.

    Iwase H, Ando Y, Ichihara S, Toyoshima S, Nakamura T, Karamatsu S, Ito Y, Yamashita H, Toyama T, Omoto Y, Fujii Y, Mitsuyama S, Kobayashi S.

    Breast Cancer. 2001;8(2):98-104.

    PMID:
    11342981
    [PubMed - indexed for MEDLINE]
    4.

    Breast cancer single-nucleotide polymorphisms: statistical significance and clinical utility.

    Offit K.

    J Natl Cancer Inst. 2009 Jul 15;101(14):973-5. Epub 2009 Jun 30. No abstract available.

    PMID:
    19567420
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].

    Ruibal A, Schneider J, Arias J, del Río MC, Núnez MJ, Tejerina A.

    Rev Esp Med Nucl. 2000 Jun;19(3):244-6. Spanish. No abstract available.

    PMID:
    11062090
    [PubMed - indexed for MEDLINE]
    6.

    [Molecular protocol for HER2/neu analysis in breast carcinoma].

    Artufel MV, Valero AC, Lladó RR, Sagalés NE, Llorca MC, Carazo AM, Cardó CC, Torrus XP.

    Clin Transl Oncol. 2005 Dec;7(11):504-11. Spanish.

    PMID:
    16373062
    [PubMed - indexed for MEDLINE]
    7.

    Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.

    Rao AV, Mohammed WA, Ragoonanan C, Omo-Igbinomwanhia NE.

    West Indian Med J. 2002 Mar;51(1):4-9.

    PMID:
    12089875
    [PubMed - indexed for MEDLINE]
    8.

    Triple-negative breast cancer: disease entity or title of convenience?

    Carey L, Winer E, Viale G, Cameron D, Gianni L.

    Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. Epub 2010 Sep 28. Review.

    PMID:
    20877296
    [PubMed - indexed for MEDLINE]
    9.

    Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.

    Milne RL, Benítez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Bremer M, Hillemanns P, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Liu J, Li Y, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G, Beesley J; kConFab Investigators; AOCS Group, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Justenhoven C, Ko YD, Haas S, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Turnbull C, Hines S, Renwick A, Rahman N, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Shen CY, Wang HC, Yu JC, Chen ST, Bermisheva M, Nikolaeva T, Khusnutdinova E, Humphreys MK, Morrison J, Platte R, Easton DF; Breast Cancer Association Consortium.

    J Natl Cancer Inst. 2009 Jul 15;101(14):1012-8. Epub 2009 Jun 30.

    PMID:
    19567422
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    [Prognostic factors of breast cancer].

    Tang P, Wei B, Yang WJ, Liu YS, Bu H.

    Zhonghua Bing Li Xue Za Zhi. 2011 Feb;40(2):73-6. Chinese. No abstract available.

    PMID:
    21426799
    [PubMed - indexed for MEDLINE]
    11.

    Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

    Dabbs DJ, Chivukula M, Carter G, Bhargava R.

    Mod Pathol. 2006 Nov;19(11):1506-11. Epub 2006 Aug 25.

    PMID:
    16941011
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.

    Malamou-Mitsi VD, Syrrou M, Georgiou I, Pagoulatos G, Agnantis NJ.

    J Exp Clin Cancer Res. 1999 Sep;18(3):357-61.

    PMID:
    10606182
    [PubMed - indexed for MEDLINE]
    13.

    Prognostic significance of molecular classification of breast invasive ductal carcinoma.

    Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.

    Arch Gynecol Obstet. 2009 Jul;280(1):43-8. Epub 2008 Dec 11.

    PMID:
    19082617
    [PubMed - indexed for MEDLINE]
    14.

    [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].

    Brück P, Vilches Cisneros N, Ramos López E, Barboza Quintana O, Ancer Rodríguez J, Flores Gutiérrez JP.

    Ginecol Obstet Mex. 2006 Oct;74(10):516-22. Spanish.

    PMID:
    21961357
    [PubMed - indexed for MEDLINE]
    15.

    [Therapeutic targeting in breast cancer].

    Penault-Llorca F.

    Ann Pathol. 2009 Nov;29 Spec No 1:S71-3. Epub 2009 Oct 21. Review. French. No abstract available.

    PMID:
    19887259
    [PubMed - indexed for MEDLINE]
    16.

    [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].

    Sánchez Salmón A, Argibay S, Arias JI, Ruibal A.

    Rev Esp Med Nucl. 2005 May-Jun;24(3):185-90. Spanish.

    PMID:
    15847785
    [PubMed - indexed for MEDLINE]
    17.

    Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.

    Allred DC.

    J Natl Cancer Inst. 2010 May 5;102(9):585-7. Epub 2010 Apr 28. No abstract available.

    PMID:
    20427432
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?

    Tubbs RR, Stoler MH.

    Mod Pathol. 2000 Jan;13(1):1-3. No abstract available.

    PMID:
    10658903
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.

    Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C.

    Am J Clin Pathol. 2001 May;115(5):709-18.

    PMID:
    11345835
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk